Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management for Early-Stage Cardiovascular-Kidney-Metabolic Syndrome

29. september 2026 opdateret af: Pei-Shan, Tsai, Taipei Medical University

AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management for Early-Stage Cardiovascular-Kidney-Metabolic Syndrome: A Randomized Controlled Trial

This randomized controlled trial will evaluate the effectiveness of an AI chatbot-enabled electronic patient-reported outcome (ePRO) monitoring and nurse-led self-management intervention for adults with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. A total of 80 participants will be randomly assigned to either the intervention or control group and followed for 6 months. Participants in the intervention group will complete weekly ePRO assessments through an AI-enabled platform and receive individualized feedback, self-management support, and nurse-led clinical follow-up when indicated. Participants in the control group will receive usual care and complete weekly ePRO assessments through a non-AI platform without automated feedback or structured nurse-led support. Outcomes will be assessed at baseline, 3 months, and 6 months and will include patient-reported health outcomes, patient activation, health literacy, healthcare utilization, and changes in CKM syndrome stage.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This two-arm, parallel-group randomized controlled trial will evaluate the effectiveness of an AI chatbot-enabled electronic patient-reported outcome (ePRO) monitoring and nurse-led self-management intervention for adults with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. A total of 80 adults aged 40 years or older with stage 1 or stage 2 CKM syndrome will be recruited from one tertiary hospital in Northern Taiwan and followed for 6 months. Participants will be randomly assigned in a 1:1 ratio using computer-generated permuted block randomization with randomly varying block sizes of 4 and 6 and allocation concealment.

Participants in the intervention group will receive usual outpatient care plus an AI chatbot-enabled ePRO monitoring and nurse-led self-management intervention. The AI-enabled platform will support weekly ePRO monitoring, individualized feedback, self-management support, and risk identification. Nurses will review clinically significant alerts and provide individualized support, care coordination, and clinical escalation when indicated.

Participants in the control group will receive usual outpatient care and complete weekly ePRO assessments through a non-AI platform without automated feedback, individualized recommendations, risk alerts, or nurse-led follow-up based on their weekly ePRO responses.

Primary outcomes include the seven PROMIS-29 domain-specific T-scores and the 0-10 Pain Intensity score. Secondary outcomes include patient activation, health literacy, healthcare utilization, and changes in CKM syndrome stage. Patient-reported health outcomes, patient activation, health literacy, and CKM syndrome stage will be assessed at baseline, 3 months, and 6 months, while healthcare utilization will be assessed prospectively over the 6-month follow-up period, with data collected at 3 and 6 months and updated through interim participant reports.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

80

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Pei-Shan Tsai, PhD in Nursing
  • Telefonnummer: 27709 +886 2 2736 1661
  • E-mail: ptsai@tmu.edu.tw

Studiesteder

    • No. 250號, Wuxing St, Xinyi District, Taipei City, 110
      • Taipei, No. 250號, Wuxing St, Xinyi District, Taipei City, 110, Taiwan
        • Taipei Medical University

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

40 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

***Inclusion Criteria***

  • Adults aged ≥40 years
  • Meet the criteria for stage 1 or stage 2 cardiovascular-kidney-metabolic (CKM) syndrome
  • Receive regular outpatient care at the study hospital
  • Able to communicate in Chinese
  • Able to provide written informed consent and complete the required study assessments
  • Have access to a smartphone or tablet compatible with the study ePRO platform

***Exclusion Criteria***

  • Meet the criteria for stage 3 or stage 4 CKM syndrome, including known subclinical cardiovascular disease, a stage 3 cardiovascular risk equivalent, or established clinical cardiovascular disease
  • Have kidney failure requiring chronic kidney replacement therapy
  • Have a terminal illness with a life expectancy of <6 months
  • Have cognitive impairment that, in the judgment of the treating physician or research team, precludes informed consent or meaningful participation in the intervention
  • Are currently participating in another interventional study that could substantially influence the study outcomes

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management

Participants will receive usual outpatient care plus a 6-month AI chatbot-enabled ePRO monitoring and nurse-led self-management program, including weekly ePRO assessments, individualized feedback, self-management support, risk alerts, and nurse-led follow-up when indicated.

Participants in the intervention group will receive a six-month nurse-led, AI chatbot-enabled symptom monitoring and self-management program integrating weekly ePRO assessments. The intervention begins with a structured nurse-led intake session including CKM assessment, symptom review, goal setting, and training on chatbot use. Participants complete weekly PROMIS-29 v2.1 assessments via a smartphone-based chatbot, which provides automated, rule-based feedback, self-management guidance, and motivational prompts. A risk-stratification algorithm generates alerts when symptom deterioration is detected. Nurses review alerts daily and provide follow-up via messaging, teleconsultation, or referral depending on severity, with same-day escalation for high-risk symptoms.

Andet: Control group

Participants will receive usual outpatient care and complete weekly ePRO assessments through a non-AI platform without automated feedback, individualized recommendations, risk alerts, or structured nurse-led support based on their weekly ePRO responses.

Usual care based on standard outpatient follow-up, without access to the AI chatbot or nurse-led coordination

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
PROMIS-29 v2.1 Domain-Specific T-Scores and Pain Intensity
Tidsramme: Baseline, 3 months, and 6 months

The PROMIS-29 v2.1 Traditional Chinese version will be used to assess seven health domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference. Each domain contains four items and will be scored separately and converted to standardized T-scores with a reference-population mean of 50 and standard deviation of 10. Higher T-scores indicate greater symptom burden for Anxiety, Depression, Fatigue, Sleep Disturbance, and Pain Interference, whereas higher T-scores indicate better health for Physical Function and Ability to Participate in Social Roles and Activities. Pain Intensity will be assessed separately using a single 0-10 numeric rating scale, with higher scores indicating greater pain intensity.

Baseline, 3 months, and 6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Patient Activation Measure-13 (PAM-13)
Tidsramme: Baseline, 3 months, and 6 months.

Patient activation will be assessed using the 13-item Patient Activation Measure (PAM-13), which evaluates individuals' knowledge, skills, and confidence in managing their health. Items are rated on a 5-point response scale, including a "not applicable" option. Raw scores are converted to a 0-100 scale, with higher scores indicating greater patient activation.

Baseline, 3 months, and 6 months.
Mandarin Multidimensional Health Literacy Questionnaire (MMHLQ)
Tidsramme: Baseline, 3 months, and 6 months.

Health literacy will be assessed using the 20-item Mandarin Multidimensional Health Literacy Questionnaire (MMHLQ), which covers five domains: obtaining, understanding, evaluating, and applying health information, as well as communication and interaction. Each item is rated on a 4-point scale from very difficult to very easy. Scores are transformed to a 0-50 scale, with higher scores indicating better health literacy. Scores are categorized as insufficient (0-25), limited (>25-33), sufficient (>33-42), and excellent (>42-50).

Baseline, 3 months, and 6 months.
Healthcare Utilization
Tidsramme: Enrollment to 3 months and 3 months to 6 months

Healthcare utilization will be assessed prospectively based on participant self-report of the number of emergency department visits and hospitalizations occurring during each follow-up interval. Participants will also be encouraged to report such events through the study platform between scheduled assessments.

Enrollment to 3 months and 3 months to 6 months
Change in CKM Syndrome Stage
Tidsramme: Baseline, 3 months, and 6 months

CKM syndrome stage will be assessed using available clinical and laboratory information and participant-reported updates. Changes from baseline will be categorized as progression to a more advanced CKM syndrome stage or improvement to a lower stage.

Baseline, 3 months, and 6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. oktober 2026

Primær færdiggørelse (Anslået)

31. juli 2027

Studieafslutning (Anslået)

31. juli 2029

Datoer for studieregistrering

Først indsendt

23. april 2026

Først indsendt, der opfyldte QC-kriterier

5. maj 2026

Først opslået (Faktiske)

11. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • N202603080

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data (IPD) will not be publicly shared due to ethical and privacy considerations. However, de-identified datasets may be made available to qualified researchers upon reasonable request after publication, subject to approval by the corresponding author and the Institutional Review Board (IRB) of Taipei Medical University. Data sharing will comply with institutional policies and applicable data protection regulations

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .